Latest News

Chile approves use of Sinovac on children aged 6 years and above 

Chile has green-lighted the use of the Sinovac COVID-19 vaccines to children aged 6 years old and above. 

This is part of the South American country to boost its vaccination campaign. 

The Latin country has already approved the use of the Pfizer Inc/BioNTech vaccine for children over 12, with 654,053 receiving at least one dose since May.

An estimated 13 million of the country’s population have been inoculated by Sinovac. 

“This is great news for school-age children and those that were not included in previous vaccination plans,” said Health Minister Enrique Paris in a Reuter’s report. 

Five of the experts on the evaluation panel at the Institute of Public Health (ISP) voted in favor of applying the shot to children over 6, while two voted in favor of issuing it only to those over 12.

The Sinovac vaccines also have an emergency use approval for children in Indonesia and China. 

 

Mark Nituma

Mark Nituma is a skilled journalist whose career is defined by his unwavering dedication to storytelling and his passion for uncovering the untold stories. After graduating from the University of the Philippines Diliman, Mark began his journey in the media industry as a researcher for the internationally-awarded TV magazine show Kapuso Mo, Jessica Soho, before eventually becoming a producer. Over the years, Mark's journalism career has taken him to some of the most beautiful and least visited places in the Philippines. His ability to capture unique perspectives on life in diverse communities is truly remarkable and has enabled him to rise through the ranks. Today, as the editorial director of TFT, Mark plays a critical role in ensuring that the publication upholds the highest standards of journalistic integrity. His leadership and dedication have helped to shape TFT into one of the leading sources of news and information for Filipinos in the UAE and the Middle East. If you have a story to pitch or simply want to connect, you can reach him at [email protected].

Related Articles

Back to top button